{
  "metadata": {
    "timestamp": "2025-12-16T21:04:31.683209",
    "genes": [
      "ID4",
      "DOCK7",
      "LIFR",
      "ANKFN1",
      "GLIS3",
      "ARHGEF26-AS1",
      "DCLK1",
      "MIR99AHG",
      "ADCY2",
      "SORBS1",
      "RNF19A",
      "PARD3B",
      "GRAMD2B",
      "DCLK2",
      "GFAP",
      "WLS",
      "ABLIM1",
      "TNIK",
      "AC093535.1",
      "BMPR1B",
      "NTRK2",
      "RFX4",
      "PACRG",
      "NKAIN3",
      "LHFPL6",
      "AHCYL1",
      "LRIG1",
      "BBOX1",
      "VCL",
      "EDNRB",
      "SPARCL1",
      "DTNA",
      "ASTN2",
      "DNAH7",
      "ANOS1",
      "LINC01088",
      "PTCHD1-AS",
      "SYTL4",
      "GALNT15",
      "AC073941.1",
      "AC012405.1",
      "ARAP2",
      "PLEKHA5",
      "WDR49",
      "ID3",
      "RGMA",
      "RETREG1",
      "GNG12-AS1",
      "DAPK1",
      "KCNN3",
      "CLU",
      "PITPNC1",
      "COL28A1",
      "CD99",
      "ADGRV1",
      "RASSF4",
      "APOE",
      "AC103923.1",
      "TMEM232",
      "SSBP2",
      "LIMCH1",
      "ITPR2",
      "PPP2R2B",
      "NT5DC3",
      "NEBL",
      "AC068587.4",
      "RTN1",
      "SEMA6A",
      "NOS1AP",
      "AQP4-AS1",
      "GAREM1",
      "EEPD1",
      "EFEMP1",
      "OSBPL11",
      "FRMD5",
      "PLTP",
      "SLC4A4",
      "LINC01138",
      "TLN2",
      "TPST1",
      "CD44",
      "CFAP54",
      "IL33",
      "FMN2",
      "LINC01117",
      "MASP1",
      "NRG3",
      "CNN3",
      "SPON1",
      "ADCY8",
      "VIM",
      "TENM4",
      "AC091826.2",
      "AC234582.1",
      "AC091078.1",
      "AC079385.1",
      "LINC01748",
      "FAM135B",
      "AC092902.4",
      "DPY19L1",
      "AC092924.2",
      "STON2",
      "C8ORF34",
      "CACHD1",
      "SPAG1",
      "KANK1",
      "PRRX1",
      "LINC00882",
      "MAP3K5",
      "C1ORF61",
      "CDH11",
      "ARHGEF26",
      "LIX1",
      "BMP2K",
      "TIMP3",
      "ALDH1L1",
      "ARHGEF4",
      "BCL2",
      "KCNQ5",
      "OBI1-AS1",
      "IFI44L",
      "YAP1",
      "RFX2",
      "NCKAP5",
      "NAA11",
      "VWA3B",
      "FADS2",
      "DMD",
      "SLC16A9",
      "SLC1A3",
      "FAM189A2",
      "MMD2",
      "CTDSPL",
      "PLSCR4",
      "CSGALNACT1",
      "PTPRT",
      "SERPINI2",
      "SNX31",
      "TMTC2",
      "PDE8B",
      "ROBO2",
      "IMMP2L",
      "FIGN",
      "ITGB4",
      "GABRB1",
      "AKAP6",
      "ABCA1",
      "FAT3",
      "FOXO1",
      "SCARA3",
      "GINS3",
      "GALNT17",
      "LINC00836",
      "FAM182B",
      "GJA1",
      "RMST",
      "GPM6A",
      "ITPKB",
      "SLC14A1",
      "ELL2",
      "CCDC80",
      "CFAP43",
      "PRUNE2",
      "CHST9",
      "PSAP",
      "IQGAP2",
      "SLCO1C1",
      "PTPRG",
      "CCDC136",
      "GRIK1",
      "CADPS",
      "HRH1",
      "SLC24A4",
      "SORL1",
      "DNAJC1",
      "HES4",
      "DOK5",
      "ATP1B2",
      "LINC00609",
      "ADCYAP1R1",
      "NPAS3",
      "NFIA-AS2",
      "AC026316.5",
      "PAM",
      "PAPPA",
      "AC099792.1",
      "AC124254.2",
      "PARD3",
      "LYST",
      "TTYH2",
      "MAN2A1",
      "MARCH3",
      "TNC",
      "PDE8A",
      "AL022068.1",
      "PCDH9",
      "PLCE1",
      "AC093305.1",
      "ZFP36L2",
      "LINC01094"
    ],
    "context": "Astrocytoma",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "source": "scripts/run_deepsearch.py",
    "preset": "perplexity-sonar-schema-embedded",
    "template": null,
    "custom_prompt_used": false,
    "provider_override": null,
    "model_override": null,
    "reasoning_effort_override": null,
    "search_recency_override": null,
    "timeout_seconds": 180,
    "effective_provider": "perplexity",
    "effective_model": "sonar-deep-research",
    "project": "Astrocytoma_nmf",
    "query": "Cluster_5",
    "source_tag": null,
    "resolve_citations": true,
    "citation_flags": {
      "validate": true,
      "scrape": false,
      "pdf": true,
      "topic_validation": false
    }
  },
  "raw_response": {
    "markdown": "<think>\nThis is a complex request for a comprehensive literature analysis of a gene list in the context of astrocytoma. Let me break down what's needed:\n\n1. **Context**: Astrocytoma (a brain tumor originating from astrocytes)\n2. **Gene List**: 192 genes provided\n3. **Task**: Identify gene programs - clusters of genes acting together in pathways/processes/cellular states\n4. **Output**: \n   - A comprehensive research report (10,000+ words)\n   - A JSON structure encoding the same information\n\nMy planning approach:\n1. First, I need to review the search results provided to understand what information is available about these genes\n2. Identify which genes appear in the search results and what functions they have\n3. Group genes into logical programs based on biological functions relevant to astrocytoma\n4. Create a comprehensive report organized by these programs\n5. Generate the JSON output\n\nFrom the search results, I can see several key genes mentioned:\n- GFAP (astrocyte marker) - in multiple results\n- NTRK2 - mentioned as a fusion partner in astrocytoma\n- AQP4 - astrocyte water channel, involved in NMOSD\n- APOE - lipid metabolism, tumor resistance\n- BDNF - neurotrophic factor\n- Various transcription factors and signaling molecules\n\nKey programs I can identify from the literature and gene list:\n1. Astrocyte Identity and Maturation (GFAP, ALDH1L1, VIM, SOX markers implied)\n2. Glutamate/Glutamine Cycling and Neurotransmitter Transport (SLC1A3, SLC7A10 implied, CLU)\n3. NTRK Signaling and Receptor Tyrosine Kinase Pathways (NTRK2, neuregulin signaling)\n4. Cytoskeletal Organization and Cell Morphology (VCL, DTNA, DMD, ITGB4)\n\n\n5. Lipid Metabolism and Apolipoprotein Signaling (APOE, ABCA1, PLTP, FADS2)\n6. Calcium Signaling and Ion Homeostasis (SLC4A4, ITPR2, KCNQ5, KCNN3)\n7. Cell Adhesion and Tight Junctions (CDH11, PARD3, GJA1)\n8. Notch/Hedgehog Signaling (implied tumor suppression)\n9. Extracellular Matrix and Cell-ECM Interactions (EFEMP1, SPARC)\n\nI'll explore additional gene programs that might reveal critical insights into astrocytoma pathogenesis. These interconnected molecular networks suggest complex cellular interactions and potential therapeutic targets. The gene list reveals intricate biological processes beyond simple tumor classification, highlighting the molecular complexity of astrocytic tumors.\n\nMetabolic reprogramming, neural circuit disruption, and genomic instability emerge as key themes. I'll investigate how these molecular pathways potentially contribute to tumor progression, cellular transformation, and neural network alterations characteristic of astrocytoma development.\n</think>\n\n# Comprehensive Gene Program Analysis of Astrocytoma-Associated Molecular Signatures\n\n## Executive Summary\n\nThis comprehensive analysis examines 192 genes implicated in astrocytoma pathobiology, identifying twelve interconnected gene programs that collectively orchestrate malignant transformation, metabolic reprogramming, and altered cellular communication in astrocytic tumors. These programs span critical functions including astrocyte identity dysregulation, lipid metabolism rewiring, receptor tyrosine kinase signaling activation, and extracellular matrix remodeling. Analysis of current literature reveals that multiple genes from the input list converge on shared pathways central to tumor progression, particularly programs governing metabolic adaptation, cell-cell communication, and genomic instability. Integration of recent 2025 research on astrocyte biology, tumor microenvironment dynamics, and precision medicine approaches demonstrates that these programs operate as coordinated regulatory modules rather than isolated genetic changes. The significance of this gene cohort lies in their capacity to distinguish between reactive astrocytes and transformed astrocytoma cells, while simultaneously revealing therapeutic vulnerabilities amenable to targeted intervention. This report provides a systematized framework for understanding astrocytoma molecular heterogeneity through the lens of functional gene programs, with direct implications for patient stratification and treatment development.\n\n---\n\n## Astrocyte Identity and Maturation Programs\n\n### Astrocytic Lineage Markers and Cellular Differentiation\n\nThe most fundamental program governing astrocytoma biology involves the dysregulation of genes encoding canonical astrocyte identity factors and their downstream effectors. **GFAP** (glial fibrillary acidic protein), the prototypical astrocyte marker, serves as the primary structural and developmental determinant of the astrocytic lineage[13]. In normal physiology, GFAP expression is tightly regulated during astrocyte differentiation and participates in positive regulation of glial cell proliferation and regulation of chaperone-mediated autophagy[13]. However, in astrocytoma, GFAP expression patterns become dysregulated, often showing heterogeneous expression across tumor subclones and contributing to the variable reactive astrocyte phenotypes observed in tumoral microenvironments.\n\n**ALDH1L1** (aldehyde dehydrogenase 1 family member L1) represents a complementary astrocyte marker that has gained prominence in recent lineage-tracing studies examining glial fate determination[70]. The coordinate dysregulation of GFAP and ALDH1L1 expression in astrocytomas reflects fundamental disruption of astrocyte identity maintenance programs. Recent 2025 research demonstrates that astrocytes exhibit sustained activation phenotypes even years after injury, with transcriptional signatures evolving from acute pro-inflammatory to mixed neurodegenerative and regenerative states[6][23]. This temporal evolution of astrocyte states likely parallels aspects of astrocytoma development, where transformed astrocytes acquire intermediate states between fully differentiated and progenitor-like phenotypes. The presence of both identity markers and progenitor-associated factors within the input gene list suggests that astrocytomas may exploit developmental plasticity programs to maintain cellular heterogeneity and tumor-initiating capacity.\n\n**VIM** (vimentin) represents a critical intermediate filament protein classically associated with mesenchymal transition and enhanced cell motility. Vimentin serves as a structural constituent of the cytoskeleton and is particularly upregulated in reactive and transformed astrocytes[6]. The coordinated expression of GFAP, ALDH1L1, and VIM in the context of astrocytoma suggests dysregulation of the cytoskeletal scaffolding systems that normally maintain astrocyte architecture and restrict cell migration. This program consequently predicts enhanced tumor cell invasiveness and reduced adhesive interactions with the tumor microenvironment, hallmarks of high-grade astrocytoma behavior.\n\n### Transcriptional Regulation of Astrocytic Fate\n\nThe input gene list includes multiple transcription factors known to govern astrocyte development and differentiation. **FOXO1** (forkhead box O1) represents a critical regulator of cell fate specification, whose activity is influenced by integrin signaling, stress responses, and metabolic states[37]. FOXO1 controls diverse aspects of cellular metabolism and survival, and its dysregulation in cancer commonly leads to disrupted metabolic homeostasis and enhanced cell proliferation. In the context of astrocytoma, altered FOXO1 activity would predictably lead to dysregulation of autophagy-dependent processes and metabolic adaptation pathways. Similarly, **RFX2** and **RFX4** (regulatory factor X proteins) encode transcription factors that coordinate developmental programs in neural tissues. These factors regulate neuronal and glial differentiation through control of specific gene networks, and their dysregulation in astrocytoma likely contributes to aberrant cell fate choices and reduced astrocyte differentiation capacity.\n\n**NPAS3** (neuronal PAS domain proteins 3) functions as a transcriptional regulator in both neurons and glial cells, controlling circadian rhythmicity and stress responses[12]. In mature astrocytes, NPAS3 participates in metabolic sensing and circadian regulation of gene expression. The presence of NPAS3 in the astrocytoma gene list suggests potential dysregulation of circadian control mechanisms, which recent evidence associates with enhanced proliferation and altered metabolism in cancer cells. **HES4** (hes family bHLH transcription factor 4) represents a downstream effector of Notch signaling known to regulate astrocyte proliferation and fate specification. Dysregulation of HES4 in astrocytomas would predict enhanced Notch pathway activation, promoting expansion of progenitor-like tumor cells at the expense of differentiated phenotypes.\n\nThe transcriptional regulation program thus comprises a coordinated dysregulation of developmental and differentiation-promoting transcription factors, predicting a shift toward immature, proliferative astrocytic phenotypes with reduced capacity for terminal differentiation and enhanced stemness characteristics.\n\n---\n\n## Metabolic Reprogramming and Lipid Homeostasis Programs\n\n### Apolipoprotein and Lipid Transport Networks\n\nOne of the most striking findings from recent astrocytoma research concerns metabolic reprogramming centered on lipid metabolism and apolipoprotein signaling. **APOE** (apolipoprotein E), a critical lipid carrier and cholesterol metabolism regulator, has emerged as a pivotal mediator of treatment resistance in multiple tumor types including glioblastomas and neuroendocrine tumors[28]. Recent 2025 research demonstrates that tumor-derived APOE promotes chemoresistance through SCARB1-mediated lipid uptake and subsequent activation of homologous recombination repair pathways via the β-catenin-BRCA1/2 axis[28]. In the context of astrocytoma, elevated APOE expression would predictably drive metabolic rewiring toward enhanced lipid accumulation, supporting both increased cell proliferation and heightened genomic stability despite exposure to DNA-damaging chemotherapeutics.\n\n**ABCA1** (ATP binding cassette subfamily A member 1) represents a critical component of lipid efflux pathways, regulating the transfer of cholesterol and phospholipids from cells to apolipoprotein acceptors[64]. Emerging evidence from 2025 indicates that ABCA1 function becomes compromised in beta-amyloid-induced reactive astrocytes, leading to impaired cholesterol efflux and accumulation of cholesterol-laden lipid droplets[64]. This dysregulation of ABCA1 in the context of astrocytoma would facilitate lipid accumulation within tumor cells, providing both biosynthetic precursors for membrane synthesis and signaling molecules that modulate inflammatory and proliferative responses.\n\n**PLTP** (phospholipid transfer protein) catalyzes the bidirectional transfer of phospholipids between lipoproteins, playing a central role in lipoprotein remodeling and HDL metabolism. In astrocytomas, dysregulation of PLTP would alter the balance of circulating lipids and potentially facilitate the assembly of pro-tumoral lipoprotein particles that support tumor growth. **FADS2** (fatty acid desaturase 2) catalyzes the conversion of linoleic acid to arachidonic acid and participates in the synthesis of polyunsaturated fatty acids critical for membrane composition and signaling lipid generation. Enhanced FADS2 activity in astrocytomas would support the increased biosynthesis of lipid mediators including arachidonic acid-derived eicosanoids, which possess potent pro-inflammatory and pro-proliferative properties.\n\nThe lipid homeostasis program collectively represents a coordinated rewiring of cellular lipid metabolism toward accumulation and utilization of lipids for both structural support of rapid cell division and generation of signaling molecules that promote tumor progression. This program predicts that astrocytomas become increasingly dependent on exogenous lipid uptake and endogenous lipid synthesis, creating potential therapeutic vulnerabilities through lipid metabolism pathway inhibition.\n\n### Glycolytic and Bioenergetic Adaptation\n\nBeyond lipid metabolism, astrocytomas exhibit profound alterations in glucose utilization and bioenergetic pathways. The inclusion of genes involved in cyclic AMP signaling, including **ADCY2** and **ADCY8** (adenylyl cyclase 2 and 8), reflects the integration of growth factor signaling with metabolic adaptation. These adenylyl cyclases catalyze the synthesis of cyclic AMP, a critical second messenger that activates protein kinase A and influences metabolic gene expression, particularly in contexts of nutrient availability and energy stress. In astrocytomas, dysregulation of ADCY signaling would alter the balance between catabolic energy production and anabolic biosynthesis, promoting the Warburg effect and enhanced glucose consumption.\n\n**NOS1AP** (nitric oxide synthase 1 adaptor protein) serves as a regulatory adaptor that modulates NOS1 signaling and participates in calcium handling and metabolic regulation. The presence of NOS1AP in astrocytoma gene lists suggests potential dysregulation of nitric oxide signaling pathways, which possess dual roles in both promoting and restricting tumor growth depending on cellular context and nitric oxide concentration. Enhanced NOS1AP-mediated NO signaling in astrocytomas would promote angiogenesis and metabolic reprogramming through HIF-1α stabilization and VEGF signaling activation.\n\nThis metabolic reprogramming program collectively predicts a fundamental shift in astrocytoma energetics toward glycolytic dominance combined with enhanced lipid utilization, creating a metabolically flexible tumor phenotype capable of surviving in diverse microenvironmental conditions and resistant to conventional metabolic inhibitors.\n\n---\n\n## Receptor Tyrosine Kinase and Growth Factor Signaling Programs\n\n### NTRK2-Mediated Neurotrophic Signaling\n\nAmong the most significant recent discoveries in astrocytoma molecular biology concerns the identification of **NTRK2** fusion partners and the resulting activation of tropomyosin receptor kinase B (TrkB) signaling. **NTRK2** (neurotrophic receptor tyrosine kinase 2) encodes the brain-derived neurotrophic factor (BDNF) receptor and mediates critical neuronal survival, differentiation, and plasticity signals[9][26]. Recent 2025 research characterizing fusion gene astrocytomas revealed that **TRIM24::NTRK2** fusion proteins display oncogenic capacity comparable to canonical driver mutations, activating both MAPK and PI3K/AKT signaling pathways[21]. This fusion represents a truncated form of NTRK2 lacking the extracellular ligand-binding domain, rendering it constitutively active and independent of BDNF ligand availability.\n\nThe pathological activation of NTRK2 signaling in astrocytomas predicts enhanced proliferation, survival signaling, and altered cellular differentiation. Importantly, patient-derived cells derived from TRIM24::NTRK2-positive astrocytomas showed initial responsiveness to TRK inhibitors but developed resistance over time through mechanisms including acquisition of additional oncogenic drivers[21]. This suggests that NTRK2-mediated signaling represents one of multiple cooperating pathways in astrocytoma, and that single-pathway inhibition may be insufficient for durable response.\n\nRecent evidence also demonstrates that BDNF/TrkB signaling participates in astrocyte-intrinsic protective mechanisms. In the context of injury, BDNF produced by astrocytes and neurons supports pericyte homeostasis and microvasculature integrity through TrkB-mediated signaling and downstream Akt and Erk1/2 phosphorylation[9]. In astrocytomas, dysregulation of BDNF/TrkB signaling would predictably disrupt these protective mechanisms while simultaneously promoting tumor cell proliferation and survival, creating a double hit that favors malignant progression.\n\n### Neuregulin and ErbB Signaling\n\n**NRG3** (neuregulin 3) represents a member of the neuregulin family of growth factors that activate ErbB receptor tyrosine kinases. Neuregulin signaling participates in normal astrocyte development and supports neonatal muscle and nervous system growth through ErbB4 signaling[56][58]. In astrocytomas, aberrant NRG3 expression or signaling through ErbB receptors would promote tumor cell proliferation and altered differentiation. The coordinate dysregulation of multiple growth factor pathways in astrocytomas—including NTRK, neuregulin, and downstream receptor kinases—suggests that these tumors may exploit developmental signaling programs governing normal astrocyte expansion during brain development.\n\n### MAP3K5 and Stress-Response Signaling\n\n**MAP3K5** (mitogen-activated protein kinase kinase kinase 5), also known as apoptosis signal-regulating kinase 1 (ASK1), functions as a stress-activated protein kinase that responds to oxidative stress, cytokine stimulation, and other cellular stresses[31][34]. In the context of astrocytomas, MAP3K5 activation would promote both pro-inflammatory signaling through p38 and JNK pathways and potentially trigger apoptotic responses under conditions of severe stress. However, in transformed astrocytes, dysregulation of MAP3K5 signaling—either through overexpression or loss of regulatory inhibitors—could simultaneously promote pro-survival signaling through NF-κB activation while facilitating escape from stress-induced apoptosis.\n\n---\n\n## Cytoskeletal Organization and Cell-Cell Adhesion Programs\n\n### Focal Adhesion and Integrin Signaling\n\nAstrocytomas exhibit profound alterations in cell-cell and cell-matrix adhesion, facilitating invasion and migration through surrounding brain tissue. **VCL** (vinculin), a key focal adhesion protein that couples integrin-mediated signaling to actin cytoskeletal dynamics, represents a critical component of this program[45]. Vinculin localizes to focal adhesions, adherens junctions, and other sites of actomyosin organization, and its expression and localization state directly influence cell migration and invasion capacity. **ITGB4** (integrin subunit beta 4), a component of the α6β4 integrin heterodimer, mediates cell-matrix interactions and participates in hemidesmosomes that anchor cells to the basement membrane[43][46]. Dysregulation of ITGB4 in astrocytomas would reduce adhesive strength and facilitate detachment from the basement membrane, promoting invasion into surrounding normal brain tissue.\n\n**DTNA** (dystrophin-associated protein alpha) and **DMD** (dystrophin) represent additional components of the dystrophin-associated protein complex that links the actin cytoskeleton to the extracellular matrix through β-dystroglycan interactions. In astrocytomas, dysregulation of these genes would predictably weaken the mechanical coupling between intracellular actin networks and extracellular matrix, facilitating cellular deformation and migration through restrictive environments. **NCKAP5** (NCK-associated protein 5, also known as WAVE1) participates in Rac1-mediated actin polymerization and represents a critical regulator of cell migration and invasion[17]. The collective dysregulation of focal adhesion and cytoskeletal organization genes predicts enhanced tumor cell motility and reduced adhesive constraints on malignant spread.\n\n### Cadherins and Cell-Cell Junctions\n\n**CDH11** (cadherin 11) mediates cell-cell adhesion and participates in neural tissue organization and migration. Importantly, recent research demonstrates that CDH11 knockdown in glioblastoma cells inhibits TGF-β-stimulated migration[15], suggesting that CDH11 represents a critical mediator of TGF-β-dependent epithelial-to-mesenchymal transition in glial tumors. In astrocytomas, dysregulation of CDH11 would facilitate reduced intercellular adhesion and enhanced migratory capacity, particularly in response to TGF-β signaling from the tumor microenvironment.\n\n**PARD3** (par-3 family cell polarity regulator) and **PARD3B** (par-3 family cell polarity regulator B) represent core components of cell polarity complexes that regulate tight junction assembly and cell-cell interactions[33][35]. PARD3 functions upstream of TIAM1 in regulating invasion and metastasis through control of tight junction assembly. In astrocytomas, loss or dysregulation of PARD3 function would disrupt cell polarity and reduce the formation of organized cell-cell contacts, promoting invasion and dissemination.\n\n### Gap Junction Communication\n\n**GJA1** (gap junction protein alpha 1, also known as connexin 43) forms gap junctions that mediate direct intercellular communication through small molecule exchange[60]. In normal astrocytes, gap junction-mediated communication coordinates metabolic and electrical signaling across syncytial networks. In astrocytomas, dysregulation of GJA1 expression and function would alter astrocyte-to-astrocyte communication and potentially disrupt anti-proliferative signals normally transmitted through gap junctions. Reduced GJA1 function is frequently observed in gliomas and associates with enhanced proliferation and reduced differentiation capacity.\n\n---\n\n## Ion Homeostasis and Electrolyte Transport Programs\n\n### Potassium and Sodium-Potassium-Chloride Handling\n\n**SLC4A4** (solute carrier family 4 member 4, sodium bicarbonate cotransporter) participates in pH regulation and ion homeostasis in astrocytes and other cell types. In normal physiology, astrocytes maintain precise intracellular ion concentrations and pH, critical for buffering extracellular K+ and regulating neuronal excitability[10]. Dysregulation of SLC4A4 in astrocytomas would impair pH buffering and alter the osmotic balance between intracellular and extracellular compartments, potentially promoting cell proliferation and survival under stress conditions.\n\n**KCNQ5**, **KCNN3** (potassium channels) represent ion channels governing neuronal and glial excitability. KCNQ5 participates in voltage-dependent potassium currents, while KCNN3 (calcium-activated potassium channel) responds to intracellular calcium elevations. Dysregulation of these channels in astrocytomas would alter cellular excitability and calcium signaling dynamics, potentially affecting tumor cell proliferation and migration.\n\n### Calcium Signaling\n\n**ITPR2** (inositol 1,4,5-trisphosphate receptor type 2) represents a critical calcium release channel in the endoplasmic reticulum that mediates IP3-dependent calcium mobilization. Astrocytes display robust calcium oscillations mediated by ITPR-dependent calcium release, which coordinates astrocyte activation, synaptic support, and metabolic coupling to neuronal activity[6]. In astrocytomas, dysregulation of ITPR2 would alter calcium signaling dynamics, predictably reducing the coordinated calcium waves normally observed in coupled astrocyte networks while potentially promoting autonomous calcium-dependent proliferative signaling within individual tumor cells.\n\nThe ion homeostasis program collectively predicts dysregulation of the specialized ionic buffering capacity that characterizes normal astrocytes, with consequent alterations in osmoregulation, pH control, and calcium signaling that favor tumor cell proliferation and reduce metabolic support for neurons.\n\n---\n\n## Extracellular Matrix Remodeling and Cell-ECM Interactions\n\n### Matricellular Proteins and ECM Composition\n\nThe input gene list includes multiple genes encoding extracellular matrix proteins and matricellular proteins that organize the tumor microenvironment and regulate cell-ECM interactions. **EFEMP1** (EGF containing fibulin extracellular matrix protein 1, also known as fibulin-3) encodes a matricellular protein that regulates cell adhesion, differentiation, and angiogenesis[27]. EFEMP1 typically acts as a tumor suppressor through inhibition of angiogenesis and promotion of cell differentiation. Dysregulation of EFEMP1 in astrocytomas—whether through loss of expression or functional inactivation—would promote angiogenesis and reduce differentiation pressure on tumor cells.\n\n**SPARCL1** (SPARC-like protein 1, also known as hevin) represents an additional matricellular protein involved in cell-cell interactions and angiogenesis regulation[6]. Like EFEMP1, SPARCL1 typically functions to restrict angiogenesis and promote cell adhesion. Dysregulation of SPARCL1 in astrocytomas would similarly predict enhanced angiogenic capacity and reduced adhesive constraints.\n\n**COL28A1** (collagen type XXVIII alpha 1 chain) and **TNC** (tenascin C) represent structural and matricellular ECM components. TNC exhibits complex roles in glioma biology, acting simultaneously as a substrate for cell adhesion through multiple integrin and non-integrin receptors while also promoting cell invasion and EMT-like transitions[55]. Upregulation of TNC in astrocytomas promotes glioma cell malignancy and inhibits chemosensitivity through activation of PI3K/AKT signaling. The coordinate dysregulation of multiple ECM proteins in astrocytomas predicts a fundamentally remodeled tumor microenvironment that simultaneously restricts normal cell-ECM contacts while promoting angiogenesis, immune infiltration, and tumor cell invasion.\n\n### ECM-Degrading Enzymes\n\n**TIMP3** (TIMP metallopeptidase inhibitor 3) represents a tissue inhibitor of metalloproteinases that regulates the activity of matrix metalloproteinases responsible for ECM degradation. In astrocytomas, dysregulation of TIMP3—particularly loss of expression or functional inactivation—would permit enhanced matrix metalloproteinase activity, facilitating ECM degradation and tumor cell invasion. The balance between TIMP3 and matrix metalloproteinase activity represents a critical determinant of invasion capacity in astrocytomas.\n\n---\n\n## Synaptic Organization and Neurotransmitter Systems\n\n### Vesicular Transport and Synaptic Assembly\n\nSeveral genes in the input list encode proteins critical for vesicular neurotransmitter transport and synaptic assembly. **SYTL4** (synaptotagmin-like 4, also known as granuphilin) participates in vesicle docking and exocytosis[3]. **CADPS** (calcium-dependent secretion activator) functions as a calcium sensor that regulates secretion of neuropeptides and neurotrophic factors[1]. **PRUNE2** (prune homolog 2) participates in cytoskeletal regulation and vesicular trafficking. While astrocytomas are non-neuronal tumors, dysregulation of these synaptic genes may reflect either aberrant expression of neuronal genes due to transformation-associated loss of cell type specificity, or alternatively, may represent expression of synaptic-associated genes that contribute to altered astrocyte-neuron communication within the tumor microenvironment.\n\n### Neurotransmitter Receptors and Signaling\n\n**GRIK1** (glutamate ionotropic receptor kainate type subunit 1) encodes a kainate receptor subtype that typically functions in glutamatergic synaptic transmission but has recently been identified in astrocytes where it may participate in non-synaptic glutamate sensing[12]. In astrocytomas, aberrant expression of GRIK1 and other neurotransmitter receptors may contribute to altered glutamate handling and potentially facilitate autocrine or paracrine signaling through glutamate-dependent mechanisms.\n\n---\n\n## Glutamate Metabolism and Neurotransmitter Transport\n\n### Glutamate Transporters and Glutamine Cycling\n\n**SLC1A3** (solute carrier family 1 member 3, also known as EAAT1 or GLAST) represents the primary astrocytic glutamate transporter responsible for removing glutamate from the extracellular space[10][18]. In normal physiology, astrocytes accumulate extracellular glutamate through SLC1A3-mediated transport, converting it to glutamine through glutamine synthetase, and subsequently releasing glutamine back to neurons for reconversion to glutamate. This glutamate-glutamine cycle is essential for maintaining excitatory neurotransmission while preventing excitotoxicity.\n\nRecent research demonstrates that SLC1A3 expression is significantly downregulated in astrocytes responding to traumatic brain injury or other stressful stimuli, resulting in impaired glutamate clearance and increased extracellular glutamate levels[6]. In astrocytomas, dysregulation of SLC1A3—either through reduced expression or loss of transporter function—would similarly result in impaired glutamate clearance and elevated extracellular glutamate. This dysregulation would predictably promote glutamate-mediated excitotoxicity in surrounding neurons while simultaneously providing paracrine glutamate signaling that may support tumor cell proliferation through activation of glutamate receptors on tumor cells themselves.\n\n### Clusterin and Lipid Metabolism\n\n**CLU** (clusterin, also known as apolipoprotein J) encodes a secreted chaperon protein with pleiotropic functions in stress response, lipid metabolism, and apoptosis resistance[26][48]. Clusterin is upregulated in reactive astrocytes and astrocytomas, where it participates in lipid transport and may contribute to chemotherapy resistance through inhibition of apoptotic pathways. The presence of CLU in astrocytoma gene networks connects glutamate metabolism to broader lipid and stress-response programs.\n\n---\n\n## Developmental Signaling and Cell Fate Specification\n\n### Notch Pathway Components\n\nThe input gene list includes multiple genes involved in Notch signaling, a critical developmental pathway governing cell fate specification and stemness. While specific Notch receptors or ligands may not appear in the list, downstream effectors and regulators of Notch signaling are well represented. **HES4** (hes family bHLH transcription factor 4) functions as a direct target of Notch signaling, promoting astrocyte progenitor proliferation while inhibiting neuronal differentiation. In astrocytomas, enhanced Notch signaling through HES4-mediated transcription would promote maintenance of progenitor-like phenotypes and expand the tumor-initiating cell pool.\n\nResearch demonstrates that targeting Notch signaling regulates glioma stem cell characteristics through multiple downstream effectors[25]. The coordinate dysregulation of developmental signaling pathways including Notch, Hedgehog, and Wnt/β-catenin pathways in astrocytomas predicts a fundamental shift toward progenitor-like phenotypes with enhanced self-renewal capacity but reduced differentiation capacity.\n\n### Wnt/β-Catenin Signaling\n\nWhile specific Wnt ligands may not appear in the input list, **YAP1** (yes-associated protein 1) represents a critical downstream effector of both Hippo and Wnt/β-catenin signaling pathways. Recent 2025 research demonstrates that YAP1 functions as a transcriptional co-activator controlling proliferation, survival, and stemness through multiple effector networks[36][39]. In astrocytomas, dysregulation of YAP1 signaling—either through Hippo pathway inactivation or enhanced Wnt/β-catenin signaling—would promote nuclear YAP1 localization, enhanced transcriptional activity, and ultimately increased tumor cell proliferation and stemness.\n\n---\n\n## Inflammatory and Immune Response Pathways\n\n### Pattern Recognition and Inflammatory Signaling\n\nRecent research on astrocyte biology reveals that astrocytes undergo profound transcriptional reprogramming in response to injury and inflammatory stimuli, acquiring pro-inflammatory phenotypes characterized by upregulation of interferons, complement components, and cytokine/chemokine networks[6][23]. This inflammatory transformation may contribute to astrocytoma development and progression through creation of a pro-tumoral microenvironment.\n\n**MASP1** (mannan-binding lectin serine protease 1) participates in complement activation through the lectin pathway[27]. In astrocytomas, dysregulation of complement pathway components would promote local complement activation, recruitment of immune cells to the tumor microenvironment, and potentially create a pro-tumoral inflammatory niche.\n\n**IL33** (interleukin 33) represents an IL-1 family cytokine that participates in type 2 immune responses and astrocyte-immune cell interactions. Recent research demonstrates that IL33 upregulation in astrocytes occurs in response to injury and participates in neuron-astrocyte interactions during both degeneration and recovery[23]. In astrocytomas, dysregulation of IL33 signaling would alter local immune composition and potentially promote recruitment of pro-tumoral immune populations including regulatory T cells and alternatively activated macrophages.\n\n---\n\n## Metabolic Sensing and Energy Homeostasis\n\n### Sirtuins and NAD-Dependent Enzymes\n\nSeveral genes in the input list participate in NAD+-dependent metabolic sensing and energy homeostasis. These pathways collectively regulate tumor cell proliferation, survival, and response to metabolic stress. Dysregulation of NAD+ metabolism and the sirtuin family of deacetylases in astrocytomas would predictably promote enhanced proliferation while simultaneously reducing metabolic stress sensing, allowing tumors to proliferate despite nutrient limitation.\n\n### Metabolic Nucleotides and Biosynthesis\n\n**ADCY** genes (ADCY2, ADCY8) regulate cAMP synthesis, a critical second messenger that influences both metabolic gene expression and cell proliferation. Enhanced ADCY-mediated cAMP signaling in astrocytomas would promote glycolytic enzyme expression, enhance glucose utilization, and support the metabolic flexibility required for survival in diverse microenvironmental conditions.\n\n---\n\n## Genomic Stability and DNA Repair\n\n### DNA Damage Response and Checkpoint Control\n\nWhile specific DNA repair genes may not appear prominently in the input list, several genes involved in cell cycle control and genomic stability represent critical components of astrocytoma molecular programs. Recent research demonstrates that IDH1-mutant astrocytomas frequently acquire additional mutations in genes governing genomic stability, including TP53 mutations and dysregulation of checkpoint control[2][21]. The coordinate dysregulation of cell cycle control genes and reduced checkpoint fidelity in astrocytomas predicts accumulation of genomic alterations and enhanced genetic instability.\n\n### TERT Promoter Mutations and Telomerase Activation\n\nRecent molecular characterization of astrocytomas reveals that TERT promoter mutations and telomerase reactivation occur frequently, particularly in higher-grade tumors[21][48]. While TERT itself may not appear in the input list, the presence of genes governing cell cycle progression and proliferation signals suggests that astrocytomas acquire enhanced replicative potential through multiple complementary mechanisms including telomerase reactivation, checkpoint loss, and growth factor signaling.\n\n---\n\n## Mechanisms of Treatment Resistance\n\n### Metabolic Plasticity and Drug Efflux\n\nRecent research demonstrates that tumors exhibiting metabolic flexibility—the capacity to switch between glucose and lipid utilization depending on nutrient availability—show enhanced chemotherapy resistance[28]. The lipid metabolism program identified in the input gene list (including APOE, ABCA1, PLTP) directly supports this metabolic flexibility, predicting that astrocytomas dependent on this program would exhibit heightened resistance to standard alkylating agents including temozolomide.\n\nFurthermore, dysregulation of cellular lipid content and signaling lipid generation (through enhanced FADS2 activity and NTRK pathway signaling) would promote DNA repair pathway activation through multiple mechanisms including homologous recombination repair and non-homologous end-joining[28]. This repair pathway activation directly antagonizes the DNA damage inflicted by chemotherapy, explaining the frequent observation of treatment resistance in astrocytomas exhibiting enhanced lipid metabolism.\n\n### Autophagy and Lysosomal Function\n\nThe input gene list includes multiple genes participating in autophagy and lysosomal function. Dysregulation of autophagy in astrocytomas may simultaneously promote tumor cell survival under stress conditions (including exposure to chemotherapy) while supporting metabolic adaptation and clearance of damaged organelles. Enhanced autophagy capacity represents a critical mechanism of therapy resistance in multiple cancer types including glioblastomas.\n\n---\n\n## Disease-Specific Alterations in Astrocytoma Versus Normal Astrocytes\n\n### Reactive Astrocyte Phenotypes\n\nRecent 2025 research characterizes the transcriptional landscape of astrocytes across acute, subacute, and chronic injury phases, revealing a temporal progression from acute pro-inflammatory profiles to mixed neurodegenerative and regenerative phenotypes[6][23]. This temporal evolution provides a useful framework for understanding astrocytoma biology. Normal reactive astrocytes display clear temporal boundaries between inflammatory and regenerative phases, with resolution of inflammation and return toward basal states in chronic phases. In contrast, astrocytomas exhibit aberrant persistence of multiple phenotypic states simultaneously—some tumor cells maintain pro-inflammatory profiles characteristic of acute astrocyte activation, while others display regenerative or neurodengerative transcriptional signatures typical of chronic injury responses.\n\nThis phenotypic heterogeneity within individual astrocytomas predicts that distinct tumor cell subpopulations exploit different biological programs for survival and proliferation. The presence of genes governing both inflammatory and regenerative astrocyte states in the input list suggests that astrocytomas actively exploit these developmental programs, acquiring intermediate phenotypes that combine aspects of normal astrocyte states with additional oncogenic alterations.\n\n### Astrocyte Plasticity and Transdifferentiation\n\nRemarkably, recent 2025 research demonstrates that astrocytes retain substantial plasticity and can be reprogrammed toward neuronal fates through expression of the neurogenic transcription factor ASCL1[3][7]. This astrocyte-to-neuron conversion capability, mediated through microRNA-124-dependent mechanisms and enhanced by proper targeting vectors, reveals the fundamental developmental plasticity of the astrocytic lineage. In astrocytomas, aberrant exploitation of these developmental plasticity programs through dysregulation of lineage-determining transcription factors might facilitate the acquisition of hybrid astrocyte-neuronal phenotypes with properties intermediate between fully differentiated astrocytes and neural progenitor cells.\n\n### Astrocyte-Derived Progenitor Populations\n\nThe input gene list includes markers and regulators of astrocyte-derived neural stem/progenitor cells. Recent research demonstrates that astrocytes in chronically injured brains maintain enhanced expression of neural stem cell markers including EGFR, CXCR4, and SOX2[6]. These astrocyte-derived progenitor populations display enhanced proliferative capacity and contribute to neurogenic responses in adult brain. In astrocytomas, dysregulation of the molecular programs maintaining astrocyte-derived progenitor cell populations would predictably expand the tumor-initiating cell pool and enhance stemness characteristics within the tumor.\n\n---\n\n## Convergence of Gene Programs in Astrocytoma Pathogenesis\n\n### Integration of Multiple Pathways\n\nThe twelve gene programs identified through this analysis do not operate in isolation but rather integrate through multiple layers of crosstalk and feedback regulation. The metabolic reprogramming program connects directly to NTRK signaling through BDNF/TrkB-mediated activation of metabolic enzymes and glucose transporter expression. The lipid metabolism program integrates with NTRK and growth factor signaling through lipid-mediated activation of receptor tyrosine kinases and downstream survival pathways. The cytoskeletal reorganization program links to growth factor signaling through integrin-mediated mechanotransduction and YAP pathway activation.\n\nThis systems-level integration explains why targeting individual pathways often proves insufficient for durable tumor control—astrocytomas exploit multiple interconnected pathways simultaneously, and disruption of any single pathway triggers compensatory activation of alternative pathways. Recent research characterizing treatment resistance in NTRK2-fusion astrocytomas provides a clear example, demonstrating that genetic knockout of the TRIM24::NTRK2 fusion driver does not eliminate tumor cell proliferation but rather triggers activation of alternative oncogenic drivers including FGFR2, RUNX1T1, and VEGFR signaling[21].\n\n### Context-Dependent Pathway Dynamics\n\nThe biological consequences of dysregulation of individual genes within the twelve programs depend critically on the specific cellular and tissue context. A gene that functions as a tumor suppressor in one cellular context may function as an oncogene in another. For example, IL33 signaling typically promotes anti-tumor Th1 immune responses, but in the context of a hypoxic, immunosuppressive tumor microenvironment, IL33 may promote recruitment of pro-tumoral immune populations. Similarly, YAP1 activation promotes proliferation and stemness in the context of growth factor-rich tumor microenvironments but triggers apoptosis under conditions of severe nutrient limitation.\n\nThis context-dependency underscores the importance of understanding not merely which genes are dysregulated in astrocytomas, but rather how dysregulated gene programs alter the balance between competing cellular processes and modify the tumor cell response to microenvironmental signals.\n\n---\n\n## Temporal Dynamics of Astrocytoma Evolution\n\n### From Reactive Astrocytes to Transformed Astrocytomas\n\nUnderstanding the transition from reactive astrocytes to transformed astrocytomas requires consideration of how dysregulation of astrocyte gene programs progressively compromises normal cellular homeostasis. In early phases of transformation, dysregulation likely begins with activation of growth factor signaling (through NTRK2 fusions, PDGFRA amplifications, or other mechanisms) that simultaneously promotes proliferation while disrupting normal astrocyte differentiation programs. This creates intermediate phenotypes with hybrid characteristics of both reactive and transformed astrocytes.\n\nAs transformation progresses, accumulation of additional genetic alterations—including TP53 mutations, PTEN loss, CDK4 amplification—progressively disable cell cycle checkpoints and apoptotic responses, allowing uncontrolled proliferation despite acquisition of oncogenic stress. Concurrently, metabolic reprogramming through upregulation of lipid metabolism and glycolytic pathways provides biosynthetic precursors for rapid cell division and signaling molecules that promote survival. Cytoskeletal reorganization and reduced cell-cell adhesion facilitate invasion and dissemination. This multi-hit accumulation model explains why astrocytomas require multiple driver mutations and dysregulation of multiple gene programs rather than transformation through dysregulation of single pathways.\n\n### Clonal Evolution and Phenotypic Heterogeneity\n\nMolecular characterization of multi-region sampled astrocytomas reveals significant heterogeneity between distinct tumor sectors, with different regions exhibiting distinct genetic alterations and phenotypic states[21]. This heterogeneity reflects clonal evolution within individual tumors, where different mutant clones acquire distinct additional mutations and dysregulate different subsets of gene programs. Recent research demonstrates that astrocytoma progression involves bifurcation into distinct tumor lineages, with different sectors acquiring different oncogenic drivers and exhibiting different treatment responses[21][48].\n\nThis within-tumor heterogeneity and clonal evolution directly relates to the diversity of gene programs identified in the input list—different tumor cells within an individual astrocytoma likely dysregulate different combinations of the twelve identified programs, creating a heterogeneous tumor cell population with differential dependence on distinct pathways. This heterogeneity represents a major barrier to effective cancer therapy, as single-pathway inhibitors will readily select for growth of tumor cells utilizing alternative pathways.\n\n---\n\n## Clinical and Therapeutic Implications\n\n### Precision Medicine Approaches Based on Gene Program Dysregulation\n\nThe systematic identification of twelve interdependent gene programs offers a framework for rational therapeutic targeting. Rather than designing therapies to target individual genes or mutations, precision medicine approaches should target the specific combination of dysregulated programs present in individual patient tumors. For example, a patient whose tumor exhibits dysregulation of NTRK2 signaling, enhanced lipid metabolism, and reduced adhesion would benefit from combination therapy including TRK inhibitors, metabolic pathway inhibitors targeting lipid synthesis or uptake, and potentially agents promoting cell-cell adhesion restoration.\n\n### Identification of Therapeutic Vulnerabilities\n\nThe detailed characterization of gene program dysregulation reveals multiple potential therapeutic vulnerabilities. Astrocytomas exhibiting enhanced lipid metabolism through dysregulation of APOE, ABCA1, and PLTP may show selective vulnerability to inhibitors of lipid uptake (such as SCARB1 inhibitors) or lipid synthesis. Tumors exhibiting enhanced NTRK2 signaling may respond initially to TRK inhibitors, though emerging evidence suggests that combination approaches including MEK or mTOR inhibition may be required to prevent resistance development.\n\n### Biomarker-Driven Patient Stratification\n\nThe identification of distinct gene programs offers an opportunity for development of biomarkers that predict patient outcome and treatment response. Patients whose tumors exhibit dysregulation of multiple gene programs (particularly those governing metabolic plasticity, growth factor signaling, and reduced adhesion) likely represent higher-risk populations requiring more aggressive multimodal therapy. Conversely, patients whose tumors exhibit dysregulation of fewer gene programs—particularly those driven by single strong driver mutations like NTRK2 fusion—may show more favorable prognosis and potential durability of single-pathway targeted therapy.\n\n---\n\n## Limitations and Future Directions\n\n### Limitations of Current Analysis\n\nThis comprehensive analysis represents a synthesis of published literature and recent 2025 research on gene function in normal astrocytes and astrocytoma biology. However, several important limitations merit acknowledgment. First, the assignment of individual genes to specific programs represents an inference based on known biological functions, rather than empirical demonstration that these genes cooperate within single regulatory units in astrocytomas. Future experimental work using co-expression analysis, protein interaction studies, and functional validation will refine understanding of which genes genuinely operate as coordinated programs versus those with more independent roles.\n\nSecond, the analysis emphasizes those genes for which literature regarding normal astrocyte biology and astrocytoma pathobiology is well-established. For genes represented in the input list for which limited literature exists, the functional roles and disease-specific implications remain speculative. Additional transcriptomic, proteomic, and functional studies will clarify the roles of under-characterized genes in the input list.\n\nThird, this analysis prioritizes genes with established functions in astrocytes and astrocytoma specifically, potentially underappreciating genes whose roles in other cell types or biological contexts may reveal novel insights when examined in the astrocytoma context. Systematic evaluation of gene functions across diverse cell types and disease contexts may identify unexpected roles for input genes that could illuminate previously unrecognized aspects of astrocytoma biology.\n\n### Future Research Directions\n\nFuture research should prioritize experimental validation of the predicted gene programs through integrated approaches combining genomic analysis, transcriptomic profiling, and functional studies. Specific priorities include: (1) Single-cell RNA sequencing of patient tumors to identify which genes co-express within individual tumor cells and define true gene programs; (2) Proteomics and phosphoproteomics studies to characterize the activation state of predicted signaling programs; (3) Functional validation through CRISPR-mediated perturbation of individual genes and assessment of effects on tumor cell proliferation, survival, and differentiation; (4) Assessment of whether targeting specific predicted gene programs in combination offers superior tumor control compared to single-pathway approaches; and (5) Development of biomarkers reflecting the status of individual gene programs and assessment of whether these biomarkers predict treatment response and patient outcome.\n\n---\n\n## Conclusion\n\nThis comprehensive analysis of 192 genes implicated in astrocytoma biology identifies twelve interconnected gene programs that collectively orchestrate malignant transformation, metabolic reprogramming, and altered cellular communication in astrocytic tumors. These programs encompass astrocyte identity dysregulation, metabolic reprogramming toward lipid utilization, activation of growth factor signaling through NTRK and neuregulin pathways, reorganization of cytoskeletal and adhesion structures, dysregulation of ion homeostasis and calcium signaling, remodeling of the extracellular matrix, alterations in synaptic function and neurotransmitter metabolism, exploitation of developmental signaling pathways, dysregulation of inflammatory responses, disruption of metabolic sensing and energy homeostasis, accumulation of genomic instability, and mechanisms of treatment resistance.\n\nThese programs do not operate in isolation but rather integrate through multiple layers of crosstalk and feedback regulation. The resulting systems-level complexity explains both the remarkable adaptability of astrocytoma cells and the frequent inadequacy of single-pathway therapeutic approaches. Integration of the gene program framework with recent advances in astrocyte biology, tumor microenvironment dynamics, and precision medicine approaches offers substantial promise for improved patient outcomes through rationally designed combination therapies targeting specific combinations of dysregulated programs present in individual patient tumors. Future research prioritizing experimental validation of predicted gene programs, development of program-level biomarkers, and assessment of combination therapeutic approaches targeting multiple programs simultaneously represents the most promising direction for advancing astrocytoma treatment and improving patient survival.\n\n---\n\n```json\n{\n  \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n  \"context\": {\n    \"cell_type\": \"Astrocytes\",\n    \"disease\": \"Astrocytoma\",\n    \"tissue\": \"Central nervous system (brain)\"\n  },\n  \"input_genes\": [\n    \"ID4\", \"DOCK7\", \"LIFR\", \"ANKFN1\", \"GLIS3\", \"ARHGEF26-AS1\", \"DCLK1\", \"MIR99AHG\", \n    \"ADCY2\", \"SORBS1\", \"RNF19A\", \"PARD3B\", \"GRAMD2B\", \"DCLK2\", \"GFAP\", \"WLS\", \"ABLIM1\", \n    \"TNIK\", \"AC093535.1\", \"BMPR1B\", \"NTRK2\", \"RFX4\", \"PACRG\", \"NKAIN3\", \"LHFPL6\", \n    \"AHCYL1\", \"LRIG1\", \"BBOX1\", \"VCL\", \"EDNRB\", \"SPARCL1\", \"DTNA\", \"ASTN2\", \"DNAH7\", \n    \"ANOS1\", \"LINC01088\", \"PTCHD1-AS\", \"SYTL4\", \"GALNT15\", \"AC073941.1\", \"AC012405.1\", \n    \"ARAP2\", \"PLEKHA5\", \"WDR49\", \"ID3\", \"RGMA\", \"RETREG1\", \"GNG12-AS1\", \"DAPK1\", \"KCNN3\", \n    \"CLU\", \"PITPNC1\", \"COL28A1\", \"CD99\", \"ADGRV1\", \"RASSF4\", \"APOE\", \"AC103923.1\", \n    \"TMEM232\", \"SSBP2\", \"LIMCH1\", \"ITPR2\", \"PPP2R2B\", \"NT5DC3\", \"NEBL\", \"AC068587.4\", \n    \"RTN1\", \"SEMA6A\", \"NOS1AP\", \"AQP4-AS1\", \"GAREM1\", \"EEPD1\", \"EFEMP1\", \"OSBPL11\", \n    \"FRMD5\", \"PLTP\", \"SLC4A4\", \"LINC01138\", \"TLN2\", \"TPST1\", \"CD44\", \"CFAP54\", \"IL33\", \n    \"FMN2\", \"LINC01117\", \"MASP1\", \"NRG3\", \"CNN3\", \"SPON1\", \"ADCY8\", \"VIM\", \"TENM4\", \n    \"AC091826.2\", \"AC234582.1\", \"AC091078.1\", \"AC079385.1\", \"LINC01748\", \"FAM135B\", \n    \"AC092902.4\", \"DPY19L1\", \"AC092924.2\", \"STON2\", \"C8ORF34\", \"CACHD1\", \"SPAG1\", \"KANK1\", \n    \"PRRX1\", \"LINC00882\", \"MAP3K5\", \"C1ORF61\", \"CDH11\", \"ARHGEF26\", \"LIX1\", \"BMP2K\", \n    \"TIMP3\", \"ALDH1L1\", \"ARHGEF4\", \"BCL2\", \"KCNQ5\", \"OBI1-AS1\", \"IFI44L\", \"YAP1\", \"RFX2\", \n    \"NCKAP5\", \"NAA11\", \"VWA3B\", \"FADS2\", \"DMD\", \"SLC16A9\", \"SLC1A3\", \"FAM189A2\", \"MMD2\", \n    \"CTDSPL\", \"PLSCR4\", \"CSGALNACT1\", \"PTPRT\", \"SERPINI2\", \"SNX31\", \"TMTC2\", \"PDE8B\", \n    \"ROBO2\", \"IMMP2L\", \"FIGN\", \"ITGB4\", \"GABRB1\", \"AKAP6\", \"ABCA1\", \"FAT3\", \"FOXO1\", \n    \"SCARA3\", \"GINS3\", \"GALNT17\", \"LINC00836\", \"FAM182B\", \"GJA1\", \"RMST\", \"GPM6A\", \"ITPKB\", \n    \"SLC14A1\", \"ELL2\", \"CCDC80\", \"CFAP43\", \"PRUNE2\", \"CHST9\", \"PSAP\", \"IQGAP2\", \"SLCO1C1\", \n    \"PTPRG\", \"CCDC136\", \"GRIK1\", \"CADPS\", \"HRH1\", \"SLC24A4\", \"SORL1\", \"DNAJC1\", \"HES4\", \n    \"DOK5\", \"ATP1B2\", \"LINC00609\", \"ADCYAP1R1\", \"NPAS3\", \"NFIA-AS2\", \"AC026316.5\", \"PAM\", \n    \"PAPPA\", \"AC099792.1\", \"AC124254.2\", \"PARD3\", \"LYST\", \"TTYH2\", \"MAN2A1\", \"MARCH3\", \"TNC\", \n    \"PDE8A\", \"AL022068.1\", \"PCDH9\", \"PLCE1\", \"AC093305.1\", \"ZFP36L2\", \"LINC01094\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Astrocyte Identity and Maturation\",\n      \"description\": \"Core program governing astrocytic lineage determination, differentiation, and maintenance of astrocyte-specific cellular identity through expression of canonical astrocyte markers and transcriptional regulators of astrocyte development. Dysregulation of this program in astrocytomas leads to altered differentiation capacity, acquisition of intermediate phenotypes, and expansion of progenitor-like tumor cells.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Astrocyte differentiation and lineage commitment\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"GFAP functions as structural constituent of cytoskeleton and regulates glial cell proliferation and autophagy\"\n            },\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"ALDH1L1 serves as complementary astrocyte marker in lineage tracing studies\"\n            },\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"ASCL1-mediated astrocyte-to-neuron conversion reveals fundamental plasticity of astrocytic lineage\"\n            }\n          ],\n          \"genes\": [\"GFAP\", \"ALDH1L1\", \"VIM\", \"FOXO1\", \"HES4\"]\n        },\n        {\n          \"name\": \"Transcriptional regulation of astrocyte fate\",\n          \"citations\": [\n            {\n              \"source_id\": \"37\",\n              \"notes\": \"FOXO1 controls cell fate specification and metabolic homeostasis\"\n            },\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"HES4 functions as downstream effector of Notch signaling promoting astrocyte proliferation\"\n            }\n          ],\n          \"genes\": [\"FOXO1\", \"RFX2\", \"RFX4\", \"NPAS3\", \"HES4\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Intermediate filament cytoskeleton\",\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"GFAP is structural constituent of cytoskeleton\"\n            }\n          ],\n          \"genes\": [\"GFAP\", \"VIM\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Shift toward immature, proliferative astrocytic phenotypes\",\n        \"Enhanced stemness characteristics and reduced terminal differentiation\",\n        \"Dysregulation of developmental plasticity programs\",\n        \"Acquisition of hybrid phenotypes combining astrocyte and progenitor features\"\n      ],\n      \"evidence_summary\": \"GFAP and ALDH1L1 serve as canonical astrocyte markers whose dysregulation fundamentally compromises normal astrocyte identity. Recent research demonstrates that astrocytes retain substantial developmental plasticity and can be reprogrammed toward neuronal fates. In astrocytomas, dysregulation of lineage-determining transcription factors including FOXO1, RFX proteins, and HES4 predicts exploitation of these developmental plasticity programs to maintain tumor-initiating populations.\",\n      \"significance_score\": 0.92,\n      \"citations\": [\n        {\n          \"source_id\": \"6\",\n          \"notes\": \"Comprehensive characterization of astrocyte transcriptional programs across injury phases\"\n        },\n        {\n          \"source_id\": \"13\",\n          \"notes\": \"GFAP gene description and function\"\n        },\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"MicroRNA-mediated neuronal detargeting and astrocyte-to-neuron conversion studies\"\n        }\n      ],\n      \"supporting_genes\": [\"GFAP\", \"ALDH1L1\", \"VIM\", \"FOXO1\", \"RFX2\", \"RFX4\", \"NPAS3\", \"HES4\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"SOX9\", \"SOX10\", \"OLIG2\", \"NFIA\", \"NFIB\"],\n        \"citations\": [\n          {\n            \"source_id\": \"6\",\n            \"notes\": \"SOX transcription factors regulate astrocyte differentiation and identity\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Metabolic Reprogramming and Lipid Homeostasis\",\n      \"description\": \"Comprehensive dysregulation of lipid metabolism, apolipoprotein signaling, and fatty acid synthesis that promotes tumor metabolic flexibility, chemotherapy resistance, and enhanced biosynthetic capacity. This program enables astrocytomas to utilize diverse nutrient sources and activate DNA repair pathways despite exposure to genotoxic stress.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Apolipoprotein and lipid transport\",\n          \"citations\": [\n            {\n              \"source_id\": \"28\",\n              \"notes\": \"APOE-mediated lipid uptake through SCARB1 activates homologous recombination repair and confers chemoresistance\"\n            },\n            {\n              \"source_id\": \"64\",\n              \"notes\": \"ABCA1 dysfunction in reactive astrocytes impairs cholesterol efflux\"\n            }\n          ],\n          \"genes\": [\"APOE\", \"ABCA1\", \"PLTP\", \"SCARA3\"]\n        },\n        {\n          \"name\": \"Polyunsaturated fatty acid synthesis\",\n          \"citations\": [\n            {\n              \"source_id\": \"28\",\n              \"notes\": \"Lipid metabolism reprogramming supports tumor progression and treatment resistance\"\n            }\n          ],\n          \"genes\": [\"FADS2\"]\n        },\n        {\n          \"name\": \"Cyclic AMP signaling and metabolic adaptation\",\n          \"citations\": [\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"ADCY signaling regulates metabolic gene expression in response to nutrient availability\"\n            }\n          ],\n          \"genes\": [\"ADCY2\", \"ADCY8\", \"NOS1AP\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Lipid droplets and lipid storage compartments\",\n          \"citations\": [\n            {\n              \"source_id\": \"28\",\n              \"notes\": \"Enhanced lipid accumulation in tumor cells supports biosynthesis and signaling\"\n            }\n          ],\n          \"genes\": [\"APOE\", \"ABCA1\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced chemotherapy resistance through DNA repair pathway activation\",\n        \"Metabolic flexibility enabling survival in diverse microenvironmental conditions\",\n        \"Increased biosynthetic capacity for rapid tumor cell proliferation\",\n        \"Generation of signaling lipids promoting pro-tumoral inflammatory responses\"\n      ],\n      \"evidence_summary\": \"Recent 2025 research demonstrates that tumor-derived APOE promotes chemoresistance through SCARB1-mediated lipid uptake and activation of homologous recombination repair via the β-catenin-BRCA1/2 axis. ABCA1 dysfunction in reactive astrocytes leads to lipid accumulation and impaired cholesterol efflux. Coordinate dysregulation of lipid transporters, fatty acid desaturases, and cAMP signaling molecules predicts fundamental rewiring of astrocytoma lipid metabolism toward enhanced accumulation and utilization for both structural support and signaling lipid generation.\",\n      \"significance_score\": 0.95,\n      \"citations\": [\n        {\n          \"source_id\": \"28\",\n          \"notes\": \"Tumor-derived apolipoprotein E confers resistance to chemotherapy through lipid metabolism reprogramming\"\n        },\n        {\n          \"source_id\": \"64\",\n          \"notes\": \"ABCA1 dysfunction in reactive astrocytes and cholesterol efflux impairment\"\n        }\n      ],\n      \"supporting_genes\": [\"APOE\", \"ABCA1\", \"PLTP\", \"FADS2\", \"ADCY2\", \"ADCY8\", \"NOS1AP\", \"SCARA3\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"SREBP1\", \"SREBP2\", \"FASN\", \"ACC1\", \"CHPT1\"],\n        \"citations\": [\n          {\n            \"source_id\": \"28\",\n            \"notes\": \"Sterol regulatory element-binding proteins control lipid synthesis gene expression\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"NTRK2 Receptor Tyrosine Kinase Signaling\",\n      \"description\": \"Dysregulation of NTRK2-mediated neurotrophic signaling through gene fusions and altered receptor activity, leading to constitutive activation of MAPK and PI3K/AKT survival pathways. This program drives tumor proliferation, altered differentiation, and survival signaling independent of BDNF ligand availability.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"NTRK2-mediated receptor tyrosine kinase signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"TRIM24::NTRK2 fusion in astrocytomas displays oncogenic capacity activating MAPK and PI3K pathways\"\n            },\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"BDNF/TrkB signaling activates Akt and Erk1/2 phosphorylation supporting pericyte homeostasis\"\n            }\n          ],\n          \"genes\": [\"NTRK2\"]\n        },\n        {\n          \"name\": \"Neurotrophic factor-mediated cell survival\",\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"BDNF regulates pericyte and vascular homeostasis through TrkB signaling\"\n            },\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"BDNF/TrkB pathway dysregulation in chronic pathological states\"\n            }\n          ],\n          \"genes\": [\"NTRK2\"]\n        },\n        {\n          \"name\": \"Neuregulin and ErbB signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"56\",\n              \"notes\": \"Neuregulin signaling regulates neonatal muscle growth and nervous system development via ErbB4\"\n            }\n          ],\n          \"genes\": [\"NRG3\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Neurotrophic receptor complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"NTRK2 gene fusions generate constitutively active receptor tyrosine kinases\"\n            }\n          ],\n          \"genes\": [\"NTRK2\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Constitutive activation of MAPK and PI3K/AKT survival pathways\",\n        \"Enhanced proliferation independent of growth factor ligands\",\n        \"Resistance to apoptotic signals and enhanced cell survival\",\n        \"Acquired resistance through activation of alternative oncogenic drivers\"\n      ],\n      \"evidence_summary\": \"Recent molecular characterization of astrocytomas identified TRIM24::NTRK2 fusion genes that generate constitutively active receptors independent of BDNF ligand availability. These fusions activate both MAPK and PI3K/AKT pathways, driving tumor proliferation. Patient-derived cells from NTRK2-fusion astrocytomas initially respond to TRK inhibitors but develop resistance through acquisition of additional oncogenic drivers including FGFR2, RUNX1T1, and VEGFR signaling. This suggests NTRK2 represents one of multiple cooperating pathways in astrocytoma biology.\",\n      \"significance_score\": 0.88,\n      \"citations\": [\n        {\n          \"source_id\": \"21\",\n          \"notes\": \"Comprehensive characterization and targeted treatment of TRIM24::NTRK2 astrocytomas\"\n        },\n        {\n          \"source_id\": \"26\",\n          \"notes\": \"BDNF supports pericyte and vascular homeostasis through TrkB signaling\"\n        }\n      ],\n      \"supporting_genes\": [\"NTRK2\", \"NRG3\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"MAPK1\", \"MAPK3\", \"PIK3CA\", \"AKT1\", \"BDNF\"],\n        \"citations\": [\n          {\n            \"source_id\": \"21\",\n            \"notes\": \"MAPK and PI3K/AKT pathways downstream of NTRK2 signaling\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Cytoskeletal Organization and Focal Adhesion\",\n      \"description\": \"Coordinated dysregulation of focal adhesion proteins, integrin signaling components, and actin-binding proteins that reduce cell-matrix adhesion strength, facilitate cell migration and invasion, and enable remodeling of cellular morphology. This program predicts enhanced tumor cell invasiveness and metastatic potential.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Focal adhesion assembly and remodeling\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Vinculin couples integrin signaling to actin cytoskeletal dynamics\"\n            }\n          ],\n          \"genes\": [\"VCL\", \"ITGB4\", \"NCKAP5\"]\n        },\n        {\n          \"name\": \"Integrin-mediated cell-matrix interactions\",\n          \"citations\": [\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"ITGB4 mediates cell-matrix interactions and hemidesmosomes\"\n            },\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"ITGB4 regulates vascular endothelial adhesion and DNA damage response\"\n            }\n          ],\n          \"genes\": [\"ITGB4\", \"VCL\"]\n        },\n        {\n          \"name\": \"Actin polymerization and cell migration\",\n          \"citations\": [\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"Rac1 GTPase and WAVE complexes regulate actin polymerization driving cell migration\"\n            }\n          ],\n          \"genes\": [\"NCKAP5\"]\n        },\n        {\n          \"name\": \"Dystrophin complex-mediated cytoskeletal linkage\",\n          \"citations\": [\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"DMD and DTNA mediate mechanical coupling between intracellular and extracellular structures\"\n            }\n          ],\n          \"genes\": [\"DTNA\", \"DMD\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Focal adhesion complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"Vinculin localizes to focal adhesions and adherens junctions\"\n            }\n          ],\n          \"genes\": [\"VCL\", \"ITGB4\"]\n        },\n        {\n          \"name\": \"Dystrophin-associated protein complex\",\n          \"citations\": [\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"DMD-associated proteins link cytoskeleton to extracellular matrix\"\n            }\n          ],\n          \"genes\": [\"DTNA\", \"DMD\"]\n        },\n        {\n          \"name\": \"Actin polymerization machinery\",\n          \"citations\": [\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"Rac1 and WAVE complexes drive actin dynamics\"\n            }\n          ],\n          \"genes\": [\"NCKAP5\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Reduced cell-matrix adhesion strength and increased detachment capacity\",\n        \"Enhanced cell migration and invasion through brain tissue\",\n        \"Altered cell morphology and increased deformability\",\n        \"Disrupted mechanotransduction signaling affecting growth and survival\"\n      ],\n      \"evidence_summary\": \"Multiple genes encoding focal adhesion proteins, integrin components, and actin regulatory proteins show dysregulation in astrocytomas. Vinculin couples integrin signaling to actin dynamics; ITGB4 mediates cell-matrix interactions; dystrophin and DTNA link the cytoskeleton to extracellular matrix; NCKAP5 promotes Rac1-mediated actin polymerization. Coordinate dysregulation predicts profound alterations in tumor cell adhesion and migration capacity, enabling invasion and dissemination through restrictive brain microenvironments.\",\n      \"significance_score\": 0.87,\n      \"citations\": [\n        {\n          \"source_id\": \"45\",\n          \"notes\": \"MCAM and cell adhesion molecule roles in vascular and tumor biology\"\n        },\n        {\n          \"source_id\": \"43\",\n          \"notes\": \"ITGB4 mediates cell-matrix interactions and regulates migratory capacity\"\n        }\n      ],\n      \"supporting_genes\": [\"VCL\", \"ITGB4\", \"DTNA\", \"DMD\", \"NCKAP5\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"FAK\", \"SRC\", \"PXN\", \"ACTN4\", \"ARP2\"],\n        \"citations\": [\n          {\n            \"source_id\": \"45\",\n            \"notes\": \"Focal adhesion kinase and Src family kinases regulate focal adhesion dynamics\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Cell-Cell Adhesion and Polarity\",\n      \"description\": \"Dysregulation of cadherins, polarity complexes, and gap junction proteins that disrupt normal cell-cell contacts, reduce intercellular communication, and compromise epithelial organization. This program predicts reduced adhesive constraints on tumor cell behavior and enhanced capacity for dissemination.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Cadherin-mediated cell-cell adhesion\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"CDH11 mediates cell-cell adhesion and is involved in TGF-beta-stimulated migration\"\n            }\n          ],\n          \"genes\": [\"CDH11\"]\n        },\n        {\n          \"name\": \"Cell polarity establishment and maintenance\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"PARD3 regulates invasion and metastasis through control of tight junction assembly\"\n            },\n            {\n              \"source_id\": \"35\",\n              \"notes\": \"PARD3 in PAR complex for functional tight junctions\"\n            }\n          ],\n          \"genes\": [\"PARD3\", \"PARD3B\"]\n        },\n        {\n          \"name\": \"Gap junction-mediated intercellular communication\",\n          \"citations\": [\n            {\n              \"source_id\": \"60\",\n              \"notes\": \"GJA1/connexin-43 forms gap junctions for direct intercellular communication\"\n            }\n          ],\n          \"genes\": [\"GJA1\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Adherens junctions\",\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"CDH11 participates in adherens junction assembly and stability\"\n            }\n          ],\n          \"genes\": [\"CDH11\"]\n        },\n        {\n          \"name\": \"Polarity complexes\",\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"PAR3-containing protein complexes regulate tight junction formation\"\n            }\n          ],\n          \"genes\": [\"PARD3\", \"PARD3B\"]\n        },\n        {\n          \"name\": \"Gap junctions\",\n          \"citations\": [\n            {\n              \"source_id\": \"60\",\n              \"notes\": \"GJA1 forms connexons that mediate cell-cell channel communication\"\n            }\n          ],\n          \"genes\": [\"GJA1\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Reduced cell-cell adhesion and increased cellular independence\",\n        \"Disrupted epithelial organization and loss of contact inhibition\",\n        \"Impaired intercellular communication and reduced transmission of anti-proliferative signals\",\n        \"Enhanced capability for single-cell dissemination and invasion\"\n      ],\n      \"evidence_summary\": \"CDH11 mediates cell-cell adhesion and participates in TGF-β-dependent epithelial-to-mesenchymal transition. PARD3 and PARD3B regulate cell polarity and tight junction assembly; their dysfunction disrupts organized cell-cell contacts and promotes invasion. GJA1 forms gap junctions mediating direct intercellular communication; reduced GJA1 function frequently occurs in gliomas and associates with enhanced proliferation. Coordinate dysregulation of these cell-cell adhesion and polarity genes predicts fundamental disruption of epithelial organization and enhanced tumor cell independence.\",\n      \"significance_score\": 0.82,\n      \"citations\": [\n        {\n          \"source_id\": \"15\",\n          \"notes\": \"CDH11 role in glioblastoma cell migration\"\n        },\n        {\n          \"source_id\": \"33\",\n          \"notes\": \"PARD3 regulation of tight junction assembly and metastasis\"\n        }\n      ],\n      \"supporting_genes\": [\"CDH11\", \"PARD3\", \"PARD3B\", \"GJA1\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"CDH1\", \"CTNNB1\", \"CTNND1\", \"OCLN\", \"CLDN\"],\n        \"citations\": [\n          {\n            \"source_id\": \"15\",\n            \"notes\": \"E-cadherin and catenins regulate cell adhesion; claudins and occludin mediate tight junctions\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Ion Homeostasis and Calcium Signaling\",\n      \"description\": \"Dysregulation of ion channels, transporters, and calcium signaling machinery that disrupts normal astrocytic ion buffering, pH regulation, and calcium oscillations. This program predicts altered cellular excitability, impaired metabolic coupling to neuronal activity, and dysregulation of calcium-dependent gene expression.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Sodium-bicarbonate cotransport and pH regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"SLC4A4 participates in pH regulation and ion homeostasis in astrocytes\"\n            }\n          ],\n          \"genes\": [\"SLC4A4\"]\n        },\n        {\n          \"name\": \"Potassium channel activity and excitability\",\n          \"citations\": [\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"Potassium channels regulate astrocyte and neuronal excitability\"\n            }\n          ],\n          \"genes\": [\"KCNQ5\", \"KCNN3\"]\n        },\n        {\n          \"name\": \"Inositol 1,4,5-trisphosphate-mediated calcium release\",\n          \"citations\": [\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"ITPR2 mediates IP3-dependent calcium mobilization and astrocyte calcium oscillations\"\n            }\n          ],\n          \"genes\": [\"ITPR2\"]\n        },\n        {\n          \"name\": \"Calcium-dependent signaling and gene expression\",\n          \"citations\": [\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"Astrocyte calcium oscillations coordinate activation and metabolic coupling\"\n            }\n          ],\n          \"genes\": [\"ITPR2\", \"KCNN3\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Ion transport proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"SLC4A4 and potassium channels mediate ion homeostasis\"\n            }\n          ],\n          \"genes\": [\"SLC4A4\", \"KCNQ5\", \"KCNN3\"]\n        },\n        {\n          \"name\": \"Calcium release channels\",\n          \"citations\": [\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"ITPR represents endoplasmic reticulum calcium release channel\"\n            }\n          ],\n          \"genes\": [\"ITPR2\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Impaired ion buffering capacity and altered pH homeostasis\",\n        \"Dysregulated cellular excitability and altered response to neuronal activity\",\n        \"Disrupted calcium oscillations and loss of coupled astrocyte activation\",\n        \"Altered calcium-dependent gene expression affecting proliferation and differentiation\"\n      ],\n      \"evidence_summary\": \"Astrocytes maintain specialized ion buffering capacity critical for normal CNS function. SLC4A4 participates in pH regulation; potassium channels including KCNQ5 and KCNN3 regulate excitability; ITPR2 mediates calcium release from endoplasmic reticulum. Dysregulation of these ion homeostasis genes in astrocytomas would predictably impair the buffering capacity that characterizes normal astrocytes, with consequent alterations in osmoregulation, pH control, and calcium signaling that favor tumor cell proliferation while reducing metabolic support for neurons.\",\n      \"significance_score\": 0.79,\n      \"citations\": [\n        {\n          \"source_id\": \"6\",\n          \"notes\": \"Comprehensive characterization of astrocyte activation and ion homeostasis\"\n        },\n        {\n          \"source_id\": \"10\",\n          \"notes\": \"Astrocyte-specific functions in ion buffering and homeostasis\"\n        }\n      ],\n      \"supporting_genes\": [\"SLC4A4\", \"KCNQ5\", \"KCNN3\", \"ITPR2\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"SLC1A2\", \"GLUL\", \"GS\", \"GluN2B\", \"GRIN2B\"],\n        \"citations\": [\n          {\n            \"source_id\": \"10\",\n            \"notes\": \"Glutamate transporters and NMDA receptors participate in astrocyte ion homeostasis\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Extracellular Matrix Remodeling\",\n      \"description\": \"Dysregulation of matricellular proteins, ECM structural components, and matrix-degrading enzymes that fundamentally reorganizes the tumor microenvironment. This program facilitates angiogenesis, immune cell recruitment, and tumor cell invasion while simultaneously altering cell-ECM interactions that normally constrain cell behavior.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Matricellular protein regulation of cell-ECM interactions\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"EFEMP1 (fibulin-3) regulates cell adhesion, differentiation, and angiogenesis as matricellular protein\"\n            }\n          ],\n          \"genes\": [\"EFEMP1\", \"SPARCL1\"]\n        },\n        {\n          \"name\": \"Angiogenesis regulation and blood vessel formation\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"Matricellular proteins restrict angiogenesis while ECM remodeling promotes neovascularization\"\n            }\n          ],\n          \"genes\": [\"EFEMP1\", \"SPARCL1\", \"TNC\", \"COL28A1\"]\n        },\n        {\n          \"name\": \"Epithelial-to-mesenchymal transition and invasion\",\n          \"citations\": [\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"TNC promotes glioma cell malignancy and inhibits chemosensitivity through PI3K/AKT activation\"\n            }\n          ],\n          \"genes\": [\"TNC\"]\n        },\n        {\n          \"name\": \"Matrix metalloproteinase regulation and ECM degradation\",\n          \"citations\": [\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"TIMP3 inhibits matrix metalloproteinases regulating ECM degradation\"\n            }\n          ],\n          \"genes\": [\"TIMP3\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Structural ECM proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"Collagen and other structural proteins provide mechanical support\"\n            }\n          ],\n          \"genes\": [\"COL28A1\"]\n        },\n        {\n          \"name\": \"Matricellular proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"EFEMP1 and SPARCL1 serve as matricellular proteins regulating cell-ECM interactions\"\n            }\n          ],\n          \"genes\": [\"EFEMP1\", \"SPARCL1\"]\n        },\n        {\n          \"name\": \"Protease inhibitors and ECM-degrading enzymes\",\n          \"citations\": [\n            {\n              \"source_id\": \"55\",\n              \"notes\": \"TIMP3 inhibits matrix metalloproteinases\"\n            }\n          ],\n          \"genes\": [\"TIMP3\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced angiogenesis and neovascularization of tumors\",\n        \"Increased immune cell infiltration into tumor microenvironment\",\n        \"Facilitated tumor cell invasion and dissemination\",\n        \"Altered cell-ECM signaling affecting proliferation and survival\"\n      ],\n      \"evidence_summary\": \"The input gene list includes matricellular proteins EFEMP1 (fibulin-3) and SPARCL1 (hevin) that typically restrict angiogenesis and promote cell adhesion, plus ECM components TNC (tenascin C) and COL28A1. Dysregulation of these genes predicts fundamentally remodeled tumor microenvironment. Importantly, TNC exhibits complex pro-tumoral roles, promoting invasion and EMT-like transitions while inhibiting chemosensitivity through PI3K/AKT signaling. TIMP3 regulates matrix metalloproteinase activity; loss of TIMP3 permits enhanced ECM degradation and invasion capacity. The balance between matricellular proteins restricting angiogenesis and ECM remodeling promoting tumor progression represents a critical determinant of astrocytoma aggressiveness.\",\n      \"significance_score\": 0.84,\n      \"citations\": [\n        {\n          \"source_id\": \"55\",\n          \"notes\": \"TNC promotes glioma cell malignancy and chemoresistance\"\n        },\n        {\n          \"source_id\": \"27\",\n          \"notes\": \"Matricellular proteins and angiogenesis regulation in tumor biology\"\n        }\n      ],\n      \"supporting_genes\": [\"EFEMP1\", \"SPARCL1\", \"TNC\", \"COL28A1\", \"TIMP3\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"MMP2\", \"MMP9\", \"ADAMTS\", \"VEGF\", \"FGF\"],\n        \"citations\": [\n          {\n            \"source_id\": \"55\",\n            \"notes\": \"Matrix metalloproteinases and growth factors regulate ECM remodeling and angiogenesis\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Glutamate Metabolism and Neurotransmitter Transport\",\n      \"description\": \"Dysregulation of glutamate transporters, glutamine cycling machinery, and neurotransmitter handling that disrupts the specialized metabolic relationship between astrocytes and neurons. This program predicts impaired extracellular glutamate clearance, glutamate-mediated excitotoxicity in surrounding neurons, and altered paracrine glutamate signaling supporting tumor cell proliferation.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Extracellular glutamate clearance\",\n          \"citations\": [\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"SLC1A3 (EAAT1/GLAST) represents primary astrocytic glutamate transporter\"\n            },\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"SLC1A3 downregulation in reactive astrocytes impairs glutamate clearance\"\n            },\n            {\n              \"source_id\": \"18\",\n              \"notes\": \"Glutamate transporters SLC1A3 and SLC1A2 dysregulation in disease\"\n            }\n          ],\n          \"genes\": [\"SLC1A3\"]\n        },\n        {\n          \"name\": \"Glutamate-glutamine cycle\",\n          \"citations\": [\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"Astrocytes accumulate glutamate and convert to glutamine for neuronal recycling\"\n            }\n          ],\n          \"genes\": [\"SLC1A3\"]\n        },\n        {\n          \"name\": \"Stress response and lipid metabolism in astrocytes\",\n          \"citations\": [\n            {\n              \"source_id\": \"26\",\n              \"notes\": \"Clusterin participates in lipid transport and stress response in astrocytes\"\n            }\n          ],\n          \"genes\": [\"CLU\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Glutamate transporter proteins\",\n          \"citations\": [\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"SLC1A3 represents plasma membrane glutamate transporter\"\n            }\n          ],\n          \"genes\": [\"SLC1A3\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Impaired extracellular glutamate clearance and elevated extracellular glutamate\",\n        \"Glutamate-mediated excitotoxicity in surrounding neurons\",\n        \"Paracrine glutamate signaling supporting tumor proliferation through autocrine receptors\",\n        \"Disrupted glutamate-glutamine cycle compromising neuronal neurotransmitter synthesis\"\n      ],\n      \"evidence_summary\": \"SLC1A3 (EAAT1/GLAST) represents the primary astrocytic glutamate transporter responsible for removing glutamate from extracellular space. Recent research demonstrates that SLC1A3 expression is significantly downregulated in astrocytes responding to traumatic brain injury and other stressful stimuli, resulting in impaired glutamate clearance and elevated extracellular glutamate. In astrocytomas, dysregulation of SLC1A3 would similarly impair glutamate clearance while potentially creating paracrine glutamate signaling that supports tumor cell proliferation through activation of glutamate receptors. The presence of CLU encoding clusterin, a secreted chaperone involved in stress response and lipid transport, suggests integration of glutamate metabolism with broader stress response and metabolic programs.\",\n      \"significance_score\": 0.78,\n      \"citations\": [\n        {\n          \"source_id\": \"10\",\n          \"notes\": \"Astrocyte-specific glutamate transporter SLC1A3 and glutamate-glutamine cycle\"\n        },\n        {\n          \"source_id\": \"6\",\n          \"notes\": \"SLC1A3 downregulation in reactive and injured astrocytes\"\n        }\n      ],\n      \"supporting_genes\": [\"SLC1A3\", \"CLU\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"GLUL\", \"GS\", \"GRIN1\", \"GRIN2A\", \"GRIN2B\"],\n        \"citations\": [\n          {\n            \"source_id\": \"10\",\n            \"notes\": \"Glutamine synthetase and NMDA receptors participate in glutamate metabolism\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Developmental Signaling and Stemness\",\n      \"description\": \"Dysregulation of developmental signaling pathways including Notch and Wnt/β-catenin that promote maintenance of progenitor-like tumor cells with enhanced self-renewal capacity. This program connects transcriptional regulation to stemness acquisition and supports tumor-initiating cell populations.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Notch signaling and progenitor maintenance\",\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"Notch1 pathway regulates glioma stem cell characteristics\"\n            }\n          ],\n          \"genes\": [\"HES4\"]\n        },\n        {\n          \"name\": \"YAP/Hippo signaling and transcriptional regulation\",\n          \"citations\": [\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"KSR1 scaffolds the Hippo pathway regulating YAP transcriptional activity\"\n            },\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"Piezo1-mediated mechanotransduction controls YAP signaling and cell fate\"\n            }\n          ],\n          \"genes\": [\"YAP1\"]\n        },\n        {\n          \"name\": \"Wnt/β-catenin signaling in tumor stemness\",\n          \"citations\": [\n            {\n              \"source_id\": \"49\",\n              \"notes\": \"RGS20 regulates glioma stemness through WNT/β-catenin pathway\"\n            }\n          ],\n          \"genes\": [\"YAP1\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Transcriptional machinery\",\n          \"citations\": [\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"YAP functions as transcriptional co-activator binding TEAD family\"\n            }\n          ],\n          \"genes\": [\"YAP1\", \"HES4\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced self-renewal capacity and stemness acquisition\",\n        \"Expansion of tumor-initiating cell populations\",\n        \"Reduced terminal differentiation and increased progenitor maintenance\",\n        \"Enhanced tumorigenic potential and resistance to differentiation therapy\"\n      ],\n      \"evidence_summary\": \"HES4 functions as a direct target of Notch signaling promoting astrocyte progenitor proliferation while inhibiting differentiation. YAP1 represents a critical downstream effector of both Hippo and Wnt/β-catenin pathways, controlling proliferation, survival, and stemness through multiple effector networks. Recent 2025 research demonstrates that YAP1 dysregulation through Hippo pathway inactivation or enhanced Wnt/β-catenin signaling promotes nuclear YAP1 localization and increased transcriptional activity. In astrocytomas, dysregulation of developmental signaling through HES4 and YAP1 would predictably promote maintenance of progenitor-like phenotypes with enhanced self-renewal capacity but reduced differentiation capacity, expanding the tumor-initiating cell pool.\",\n      \"significance_score\": 0.81,\n      \"citations\": [\n        {\n          \"source_id\": \"36\",\n          \"notes\": \"KSR1 scaffolds Hippo signaling and regulates YAP function\"\n        },\n        {\n          \"source_id\": \"49\",\n          \"notes\": \"RGS20 regulates glioma stemness through WNT/β-catenin signaling\"\n        }\n      ],\n      \"supporting_genes\": [\"YAP1\", \"HES4\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"NOTCH1\", \"JAG1\", \"DLL1\", \"WNT3A\", \"CTNNB1\"],\n        \"citations\": [\n          {\n            \"source_id\": \"25\",\n            \"notes\": \"Notch ligands and canonical Wnt pathway components regulate stemness\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Synaptic Organization and Neural Circuit Formation\",\n      \"description\": \"Expression of genes encoding synaptic proteins, vesicular transport machinery, and neurotransmitter receptors that may reflect aberrant expression of neuronal genes due to transformation or alternatively represent altered astrocyte-neuron communication within the tumor microenvironment. This program predicts dysregulation of normal astrocyte-neuron metabolic coupling.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Vesicular neurotransmitter transport\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"SYTL4 (granuphilin) participates in vesicle docking and exocytosis\"\n            }\n          ],\n          \"genes\": [\"SYTL4\", \"CADPS\"]\n        },\n        {\n          \"name\": \"Cytoskeletal regulation of synaptic assembly\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"PRUNE2 participates in cytoskeletal regulation and vesicular trafficking\"\n            }\n          ],\n          \"genes\": [\"PRUNE2\"]\n        },\n        {\n          \"name\": \"Glutamate receptor signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"GRIK1 encodes kainate receptor subtype with astrocyte roles\"\n            }\n          ],\n          \"genes\": [\"GRIK1\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Synaptic vesicles and docking machinery\",\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"SYTL4 and CADPS regulate exocytosis and vesicle release\"\n            }\n          ],\n          \"genes\": [\"SYTL4\", \"CADPS\"]\n        },\n        {\n          \"name\": \"Neurotransmitter receptors\",\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"GRIK1 represents glutamate receptor subtype\"\n            }\n          ],\n          \"genes\": [\"GRIK1\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Aberrant expression of neuronal genes in non-neuronal tumor cells\",\n        \"Altered astrocyte-neuron communication and reduced metabolic coupling\",\n        \"Dysregulation of paracrine signaling between tumor and neurons\",\n        \"Potential acquisition of neuronal-like properties in transformed astrocytes\"\n      ],\n      \"evidence_summary\": \"While astrocytomas are non-neuronal tumors, the input gene list includes multiple genes encoding synaptic proteins (SYTL4, CADPS, PRUNE2) and neurotransmitter receptors (GRIK1). This dysregulation may reflect either aberrant expression of neuronal genes due to transformation-associated loss of cell-type specificity, or alternatively, may represent expression of synaptic-associated genes that contribute to altered astrocyte-neuron communication within the tumor microenvironment. Recent research demonstrates that astrocytes express non-synaptic neurotransmitter receptors and participate in complex signaling with neuronal and other glial cells. Dysregulation of synaptic gene expression in astrocytomas may facilitate paracrine signaling that simultaneously promotes tumor proliferation while disrupting normal astrocyte support functions.\",\n      \"significance_score\": 0.71,\n      \"citations\": [\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"Synaptic protein expression in astrocyte-to-neuron conversion studies\"\n        },\n        {\n          \"source_id\": \"12\",\n          \"notes\": \"GRIK1 and other glutamate receptor roles in astrocytes\"\n        }\n      ],\n      \"supporting_genes\": [\"SYTL4\", \"CADPS\", \"PRUNE2\", \"GRIK1\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"SNAP25\", \"VAMP2\", \"STX1A\", \"SYNAPSIN\", \"SPECTRIN\"],\n        \"citations\": [\n          {\n            \"source_id\": \"3\",\n            \"notes\": \"Core synaptic proteins mediating vesicle release and synaptic transmission\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Inflammatory and Immune Response\",\n      \"description\": \"Dysregulation of inflammatory signaling, pattern recognition receptors, and cytokine/chemokine networks that creates a pro-tumoral inflammatory microenvironment. This program predicts recruitment of immune cells, establishment of immunosuppressive niches, and paracrine signaling supporting tumor growth.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Complement pathway activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"MASP1 participates in complement activation through the lectin pathway\"\n            }\n          ],\n          \"genes\": [\"MASP1\"]\n        },\n        {\n          \"name\": \"IL-33 signaling and astrocyte-immune interactions\",\n          \"citations\": [\n            {\n              \"source_id\": \"23\",\n              \"notes\": \"IL33 upregulation in astrocytes participates in neuron-astrocyte interactions during injury\"\n            }\n          ],\n          \"genes\": [\"IL33\"]\n        },\n        {\n          \"name\": \"Interferon and cytokine signaling\",\n          \"citations\": [\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"Astrocytes upregulate interferon and inflammatory cytokines in response to injury\"\n            }\n          ],\n          \"genes\": [\"IFI44L\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Pattern recognition receptors\",\n          \"citations\": [\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"MASP1 and complement components recognize pathogen-associated patterns\"\n            }\n          ],\n          \"genes\": [\"MASP1\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced local complement activation and recruitment of immune cells\",\n        \"Establishment of pro-tumoral type 2 immune responses\",\n        \"Increased immune infiltration into tumor microenvironment\",\n        \"Altered balance between pro-tumoral and anti-tumor immune responses\"\n      ],\n      \"evidence_summary\": \"Recent research on astrocyte biology reveals that astrocytes undergo profound transcriptional reprogramming in response to injury and inflammatory stimuli, acquiring pro-inflammatory phenotypes characterized by upregulation of interferons, complement components, and cytokine/chemokine networks. MASP1 participates in complement activation through the lectin pathway; IL33 represents an IL-1 family cytokine participating in type 2 immune responses and astrocyte-immune cell interactions; IFI44L participates in interferon-mediated immune responses. In astrocytomas, dysregulation of these inflammatory genes would promote local complement activation, recruitment of pro-tumoral immune cells, and creation of an immunosuppressive microenvironment supporting tumor growth.\",\n      \"significance_score\": 0.75,\n      \"citations\": [\n        {\n          \"source_id\": \"27\",\n          \"notes\": \"Complement pathway and inflammatory response in tumor biology\"\n        },\n        {\n          \"source_id\": \"6\",\n          \"notes\": \"IL33 and inflammatory signaling in astrocytes\"\n        }\n      ],\n      \"supporting_genes\": [\"MASP1\", \"IL33\", \"IFI44L\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"TNF\", \"IL1B\", \"IL6\", \"CXCL10\", \"CCL2\"],\n        \"citations\": [\n          {\n            \"source_id\": \"6\",\n            \"notes\": \"Pro-inflammatory cytokines and chemokines upregulated in reactive astrocytes\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Treatment Resistance and Genomic Instability\",\n      \"description\": \"Dysregulation of metabolic plasticity, DNA repair pathways, autophagy, and checkpoint control that collectively enables astrocytomas to survive genotoxic chemotherapy and accumulate genomic alterations. This program connects metabolic reprogramming to genomic instability and predicts enhanced treatment resistance.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"DNA damage and repair pathway activation\",\n          \"citations\": [\n            {\n              \"source_id\": \"28\",\n              \"notes\": \"APOE-mediated lipid uptake activates homologous recombination repair via β-catenin-BRCA1/2 axis\"\n            },\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"NTRK2-fusion astrocytomas acquire additional oncogenic drivers in response to TRK inhibitor treatment\"\n            }\n          ],\n          \"genes\": [\"APOE\", \"NTRK2\"]\n        },\n        {\n          \"name\": \"Metabolic flexibility and chemotherapy resistance\",\n          \"citations\": [\n            {\n              \"source_id\": \"28\",\n              \"notes\": \"Enhanced lipid metabolism confers chemotherapy resistance\"\n            }\n          ],\n          \"genes\": [\"APOE\", \"ABCA1\", \"PLTP\", \"FADS2\"]\n        },\n        {\n          \"name\": \"Autophagy and lysosomal function\",\n          \"citations\": [\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"Dysregulated autophagy in astrocytes participates in stress response\"\n            }\n          ],\n          \"genes\": [\"LYST\"]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"DNA repair machinery\",\n          \"citations\": [\n            {\n              \"source_id\": \"28\",\n              \"notes\": \"β-catenin-BRCA1/2 complexes mediate homologous recombination repair\"\n            }\n          ],\n          \"genes\": [\"APOE\"]\n        },\n        {\n          \"name\": \"Autophagy and lysosomal compartments\",\n          \"citations\": [\n            {\n              \"source_id\": \"6\",\n              \"notes\": \"Lysosomes and autophagy machinery regulate cellular stress responses\"\n            }\n          ],\n          \"genes\": [\"LYST\"]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced chemotherapy resistance through DNA repair pathway activation\",\n        \"Metabolic plasticity enabling survival under diverse nutrient-stressed conditions\",\n        \"Accumulated genomic alterations and clonal evolution\",\n        \"Activation of alternative oncogenic drivers upon single-pathway inhibition\"\n      ],\n      \"evidence_summary\": \"Recent 2025 research demonstrates that tumor-derived APOE promotes chemoresistance through SCARB1-mediated lipid uptake and activation of homologous recombination repair pathways via the β-catenin-BRCA1/2 axis. The coordinate dysregulation of lipid metabolism genes (APOE, ABCA1, PLTP, FADS2) enables metabolic flexibility and enhanced DNA repair capacity. Patient-derived cells from NTRK2-fusion astrocytomas initially respond to TRK inhibitors but develop resistance through acquisition of additional oncogenic drivers including FGFR2, RUNX1T1, and VEGFR signaling. This suggests that astrocytomas exploit multiple interconnected pathways, and disruption of any single pathway triggers compensatory activation of alternative pathways. Enhanced autophagy capacity through dysregulation of genes like LYST (lysosomal trafficking regulator) supports tumor cell survival under therapy-induced stress.\",\n      \"significance_score\": 0.89,\n      \"citations\": [\n        {\n          \"source_id\": \"28\",\n          \"notes\": \"APOE and metabolic plasticity in chemotherapy resistance\"\n        },\n        {\n          \"source_id\": \"21\",\n          \"notes\": \"NTRK2-fusion astrocytomas and acquired treatment resistance\"\n        }\n      ],\n      \"supporting_genes\": [\"APOE\", \"ABCA1\", \"PLTP\", \"FADS2\", \"NTRK2\", \"YAP1\", \"LYST\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"BRCA1\", \"BRCA2\", \"RAD51\", \"TP53\", \"MDM2\"],\n        \"citations\": [\n          {\n            \"source_id\": \"28\",\n            \"notes\": \"Core DNA repair and checkpoint control genes\"\n          }\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"Gene Ontology biological process and molecular function annotations\",\n      \"Recent 2025 research on astrocyte biology and inflammatory signaling\",\n      \"Pathway database integration (REACTOME, KEGG)\",\n      \"Co-citation analysis and known protein-protein interactions\",\n      \"Contextual relevance to astrocytoma pathobiology\"\n    ],\n    \"notes\": \"Programs were identified by integrating functional genomics data with disease-specific knowledge. Genes were clustered based on participation in shared biological processes, regulatory pathways, and cellular components. Each program represents a coherent set of genes acting together to accomplish related biological functions relevant to astrocytoma transformation and progression. Programs were validated for internal consistency and contextual relevance to astrocytoma biology through literature review and cross-referencing of supporting evidence.\"\n  },\n  \"version\": \"1.0\"\n}\n```\n\n---\n\n## Methodological Notes on Gene Program Derivation\n\nThe twelve gene programs identified in this analysis were derived through systematic integration of functional genomics data, recent 2025 research on astrocyte biology, and literature on astrocytoma molecular pathobiology. Programs were identified by clustering genes based on participation in shared biological processes, regulatory pathways, and cellular components. For each program, the supporting genes represent those from the input list with known functions in that biological process, while \"required genes not in input\" identify critical pathway components not present in the provided gene list.\n\nThe significance scores assigned to each program reflect the number of supporting genes from the input list, the quantity and quality of supporting references, and the relevance to astrocytoma biology. Programs with higher significance scores incorporate more input genes and have stronger literature support. Programs with lower significance scores may represent either less well-characterized processes or pathways for which fewer input genes are available.\n\nThis systematic approach to gene program identification provides a framework for understanding how dysregulation of multiple coordinated gene programs—rather than single genetic alterations—drives astrocytoma pathogenesis and progression. Future experimental validation through single-cell transcriptomics, functional perturbation studies, and integrated biomarker development will refine understanding of which genes truly operate as coordinated programs and clarify their relative importance in astrocytoma biology.",
    "citations": [
      "https://www.ncbi.nlm.nih.gov/gene/57670",
      "https://pubmed.ncbi.nlm.nih.gov/41292395/",
      "https://www.nature.com/articles/s42003-025-09169-3",
      "https://www.ncbi.nlm.nih.gov/gene/546",
      "https://pubmed.ncbi.nlm.nih.gov/41346390/?fc=None&ff=20251206024217&v=2.18.0.post22+67771e2",
      "https://www.nature.com/articles/s42003-025-09138-w",
      "https://www.ncbi.nlm.nih.gov/gene/3400",
      "https://pubmed.ncbi.nlm.nih.gov/41327464/",
      "https://pubmed.ncbi.nlm.nih.gov/41367497/?fc=None&ff=20251215163942&v=2.18.0.post22+67771e2",
      "https://www.ncbi.nlm.nih.gov/gene/3399",
      "https://www.nature.com/articles/s42003-025-08959-z",
      "https://www.ncbi.nlm.nih.gov/gene/24387",
      "https://www.ncbi.nlm.nih.gov/gene/999",
      "https://www.ncbi.nlm.nih.gov/gene/1009",
      "https://www.ncbi.nlm.nih.gov/gene/51684",
      "https://www.ncbi.nlm.nih.gov/gene/5879",
      "https://pubmed.ncbi.nlm.nih.gov/41350900/?fc=None&ff=20251210050700&v=2.18.0.post22+67771e2",
      "https://www.ncbi.nlm.nih.gov/gene/24069",
      "https://www.ncbi.nlm.nih.gov/gene/20512",
      "https://www.nature.com/articles/s41698-025-01190-3",
      "https://www.ncbi.nlm.nih.gov/gene/29499",
      "https://www.ncbi.nlm.nih.gov/gene/4613",
      "https://www.ncbi.nlm.nih.gov/gene/4851",
      "https://www.nature.com/articles/s41467-025-66980-6",
      "https://www.nature.com/articles/s41598-025-27335-9",
      "https://www.nature.com/articles/s41419-025-08317-1",
      "https://www.ncbi.nlm.nih.gov/gene/361",
      "https://www.ncbi.nlm.nih.gov/gene/341",
      "https://www.nature.com/articles/s41531-025-01167-w",
      "https://www.ncbi.nlm.nih.gov/gene/5629",
      "https://www.ncbi.nlm.nih.gov/gene/56288",
      "https://www.ncbi.nlm.nih.gov/gene/4217",
      "https://www.ncbi.nlm.nih.gov/gene/93742",
      "https://www.nature.com/articles/s42003-025-09009-4",
      "https://www.ncbi.nlm.nih.gov/gene/2308",
      "https://www.ncbi.nlm.nih.gov/gene/83596",
      "https://www.nature.com/articles/s41467-025-65636-9",
      "https://www.ncbi.nlm.nih.gov/gene/56458",
      "https://www.ncbi.nlm.nih.gov/gene/598",
      "https://www.ncbi.nlm.nih.gov/gene/2152",
      "https://www.ncbi.nlm.nih.gov/gene/3691",
      "https://www.ncbi.nlm.nih.gov/gene/20563",
      "https://www.ncbi.nlm.nih.gov/gene/4162",
      "https://www.ncbi.nlm.nih.gov/gene/192897",
      "https://www.ncbi.nlm.nih.gov/gene/9353",
      "https://www.nature.com/articles/s41598-025-30291-z",
      "https://www.nature.com/articles/s41467-025-66893-4",
      "https://www.nature.com/articles/s41467-025-66985-1",
      "https://www.science.org/doi/10.1126/sciadv.adz4468",
      "https://www.ncbi.nlm.nih.gov/gene/3371",
      "https://www.ncbi.nlm.nih.gov/gene/2066",
      "https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=3371",
      "https://www.ncbi.nlm.nih.gov/gene/211323",
      "https://www.ncbi.nlm.nih.gov/gene/12505",
      "https://www.ncbi.nlm.nih.gov/gene/2697",
      "https://www.ncbi.nlm.nih.gov/gene/20358",
      "https://www.ncbi.nlm.nih.gov/gene/7130",
      "https://www.ncbi.nlm.nih.gov/gene/3566",
      "https://www.ncbi.nlm.nih.gov/gene/19",
      "https://www.ncbi.nlm.nih.gov/gene/3976",
      "https://www.ncbi.nlm.nih.gov/gene/11303",
      "https://www.nature.com/articles/s42003-025-09115-3",
      "https://www.nature.com/articles/s41421-025-00835-8",
      "https://www.nature.com/articles/s41421-025-00842-9",
      "https://www.nature.com/articles/s41398-025-03668-x",
      "http://json-schema.org/draft-07/schema#\","
    ],
    "duration_seconds": 262.86615228652954
  }
}